13 November 2011
HealthLinx Limited (ASX:HTX) and the Garvan Institute of Medical Research have agreed to continue their research collaboration to include a larger patient cohort following positive results from the initial study into prostate cancer.
The aim of the study was to assess the expression of proprietary HealthLinx biomarker/s in plasma samples provided by the Garvan Institute and the relationship with chemotherapy and overall survival for sufferers of prostate cancer.
Results from the initial study were promising to the point where the Garvan Institute and HealthLinx have agreed to expand the collaboration in 2012 by analysing a larger patient cohort as these samples become available.
“As predicted in the May announcement, results from the pilot studies became available in the 3rd quarter this year however needed to be analysed and interpreted before release to the market” explained HealthLinx managing director Nick Gatsios. “The company is extremely pleased with the results to date and we are looking forward to the ongoing collaboration with Garvan and the potential development of new markers to aid in prostate cancer prognosis.”
According to the Australian Institute of Health and Welfare, prostate cancer is the most common cancer diagnosed in Australia and the second greatest cause of cancer deaths in men. The latest data shows that in 2010 almost 20,000 men were diagnosed with prostate cancer. More than 3,300 men died as a direct cause of prostate cancer.